118 related articles for article (PubMed ID: 26454170)
1. Artificial regulation of p53 function by modulating its assembly.
Inobe T; Nozaki M; Nukina N
Biochem Biophys Res Commun; 2015 Nov; 467(2):322-7. PubMed ID: 26454170
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin-induced oligomer formation system of FRB-FKBP fusion proteins.
Inobe T; Nukina N
J Biosci Bioeng; 2016 Jul; 122(1):40-6. PubMed ID: 26777239
[TBL] [Abstract][Full Text] [Related]
3. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
Lubin DJ; Butler JS; Loh SN
J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor suppressor protein p53-dependent transcription by a tetramerization domain peptide via hetero-oligomerization.
Wada J; Kamada R; Imagawa T; Chuman Y; Sakaguchi K
Bioorg Med Chem Lett; 2012 Apr; 22(8):2780-3. PubMed ID: 22429466
[TBL] [Abstract][Full Text] [Related]
5. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants.
Waterman MJ; Waterman JL; Halazonetis TD
Cancer Res; 1996 Jan; 56(1):158-63. PubMed ID: 8548757
[TBL] [Abstract][Full Text] [Related]
6. Tetramer formation of tumor suppressor protein p53: Structure, function, and applications.
Kamada R; Toguchi Y; Nomura T; Imagawa T; Sakaguchi K
Biopolymers; 2016 Nov; 106(4):598-612. PubMed ID: 26572807
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
Kamada R; Nomura T; Anderson CW; Sakaguchi K
J Biol Chem; 2011 Jan; 286(1):252-8. PubMed ID: 20978130
[TBL] [Abstract][Full Text] [Related]
8. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
[TBL] [Abstract][Full Text] [Related]
9. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.
Luciani MG; Hutchins JR; Zheleva D; Hupp TR
J Mol Biol; 2000 Jul; 300(3):503-18. PubMed ID: 10884347
[TBL] [Abstract][Full Text] [Related]
10. New Phage Display-Isolated Heptapeptide Recognizing the Regulatory Carboxy-Terminal Domain of Human Tumour Protein p53.
Ben Abid S; Sahnoun M; Yacoubi-Hadj Amor I; Abdelmoula-Souissi S; Hassairi H; Mokdad-Gargouri R; Gargouri A
Protein J; 2017 Oct; 36(5):443-452. PubMed ID: 28710679
[TBL] [Abstract][Full Text] [Related]
11. Structure of the human p53 core domain in the absence of DNA.
Wang Y; Rosengarth A; Luecke H
Acta Crystallogr D Biol Crystallogr; 2007 Mar; 63(Pt 3):276-81. PubMed ID: 17327663
[TBL] [Abstract][Full Text] [Related]
12. The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain.
D'Abramo M; Bešker N; Desideri A; Levine AJ; Melino G; Chillemi G
Oncogene; 2016 Jun; 35(25):3272-81. PubMed ID: 26477317
[TBL] [Abstract][Full Text] [Related]
13. In vitro Determination of Rapamycin-triggered FKBP-FRB Interactions Using a Molecular Tension Probe.
Kim SB; Nishihara R; Fujii R; Paulmurugan R; Citterio D; Suzuki K
Anal Sci; 2019 Jan; 35(1):71-78. PubMed ID: 30504653
[TBL] [Abstract][Full Text] [Related]
14. Functional interplay between p53 and E2F through co-activator p300.
Lee CW; Sørensen TS; Shikama N; La Thangue NB
Oncogene; 1998 May; 16(21):2695-710. PubMed ID: 9652736
[TBL] [Abstract][Full Text] [Related]
15. Oxidation of methionine residue at hydrophobic core destabilizes p53 tetrameric structure.
Nomura T; Kamada R; Ito I; Chuman Y; Shimohigashi Y; Sakaguchi K
Biopolymers; 2009 Jan; 91(1):78-84. PubMed ID: 18781628
[TBL] [Abstract][Full Text] [Related]
16. Interaction between the HPV-16 E2 transcriptional activator and p53.
Massimi P; Pim D; Bertoli C; Bouvard V; Banks L
Oncogene; 1999 Dec; 18(54):7748-54. PubMed ID: 10618715
[TBL] [Abstract][Full Text] [Related]
17. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53.
Sakaguchi K; Sakamoto H; Lewis MS; Anderson CW; Erickson JW; Appella E; Xie D
Biochemistry; 1997 Aug; 36(33):10117-24. PubMed ID: 9254608
[TBL] [Abstract][Full Text] [Related]
19. The role of tetramerization in p53 function.
Chène P
Oncogene; 2001 May; 20(21):2611-7. PubMed ID: 11420672
[TBL] [Abstract][Full Text] [Related]
20. VRK1 interacts with p53 forming a basal complex that is activated by UV-induced DNA damage.
López-Sánchez I; Valbuena A; Vázquez-Cedeira M; Khadake J; Sanz-García M; Carrillo-Jiménez A; Lazo PA
FEBS Lett; 2014 Mar; 588(5):692-700. PubMed ID: 24492002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
